Last reviewed · How we verify
PERFLUBRON
Perflubron is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | PERFLUBRON |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
Common side effects
Key clinical trials
- Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anteriorly
- Fluid Filled Lung Oxygenation Assistance Trial (PHASE1)
- Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia (PHASE2)
- Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. (PHASE2)
- Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis (PHASE2)
- Measuring Cognitive Enhancement During Hyperbaric Oxygen Treatments (NA)
- Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma (PHASE2)
- Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PERFLUBRON CI brief — competitive landscape report
- PERFLUBRON updates RSS · CI watch RSS